Market Cap 42.81M
Revenue (ttm) 30.25M
Net Income (ttm) -358.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,185.88%
Debt to Equity Ratio -0.26
Volume 12,098
Avg Vol 56,218
Day's Range N/A - N/A
Shares Out 8.49M
Stochastic %K 25%
Beta 1.65
Analysts Strong Buy
Price Target $367.13

Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 516 4310
Address:
960 San Antonio Road, Palo Alto, United States
Sunnybhargava
Sunnybhargava Sep. 21 at 5:00 PM
$CMPS $ENSC $SCLX why after pain week. You pinned the stock and still no data on overdose which completes on Aug 31. And it’s only blood work for pr. It should be here by now. Why manipulation of stock prices to scare Retail. ?
0 · Reply
EnsysceBiosciences
EnsysceBiosciences Sep. 21 at 3:57 PM
$ENSC At PAINWeek, Prof. Richard Langford highlighted the profound and life-altering burden CRPS can have on patients. He shared the journey of a patient who requested amputation of an affected limb, only for symptoms to later migrate to the other lower limb. The patient ultimately became a double amputee and is now an advocate for improved care. “These stories are sadly quite common in the population of those affected.” Cases like this underscore both the complexity of CRPS and the need for new therapeutic approaches as we advance CY200 for CRPS Type 1. $SCLX $CMPS
0 · Reply
Emptybagsofcash
Emptybagsofcash Sep. 21 at 1:49 PM
$SCLX FLAT.
0 · Reply
Loonster
Loonster Sep. 21 at 1:21 PM
$SCLX BITCOIN $85K
0 · Reply
BioCEOsSukk
BioCEOsSukk Sep. 21 at 12:05 AM
$DVLT is anyone talking about the new SEC rule today about tokenization? IMO this is the regulatory win Nate mentioned that'd unlock the $SCLX Biotech Exchange. And if so I think it unlocks a big Scilex PE Consortium buyout, which would exponentially make Datavault worth a lot more because it'd have PE backing - and Scilex JV owns 950k shares they could give to Datavault pre closing that Datavault can monetize to move on the GPU expansion pre Scilex bo closing. All the above might be why Nate is so confident even though the SP is in the toilet...
3 · Reply
Emptybagsofcash
Emptybagsofcash Sep. 20 at 2:58 AM
2 · Reply
TheToaster
TheToaster Sep. 19 at 4:44 PM
$SCLX $SRNE $DVLT Let's not forget "the antibody library..." that ranged from 1 quadrillion up to 10 quadrillion antibodies. Even at the low end its equivalent to storing half a months worth of the ENTIRE global internet traffic. 😆 So many bidders during BK for that gem.
3 · Reply
Tuscion
Tuscion Sep. 19 at 4:31 PM
$DVLT $SCLX 🔥👁️
0 · Reply
Mjust
Mjust Sep. 19 at 2:39 PM
$SCLX $DVLT A similar clarification is needed for DVLT. DVLT has announced very large contracts, partnerships, revenue targets and now a $100M QEST purchase order. But investors should separate PR announcements from completed financial results. Questions I would ask: 1. How much cash has DVLT actually paid into the Available/SanQtum/Qestrel infrastructure, and where did that cash come from? 2. How much of the previously announced ~$750M in tokenization contracts has actually become GAAP-recognized revenue and cash collected? 3. Who is the counterparty behind the $100M QEST PO, what are the performance/payment terms, and how much has actually been paid? 4. How will the economics with Available/AP Cyber affect the amount DVLT actually recognizes or retains? 5. Has SCLX actually funded any of its proposed $120M contribution? The filings I’ve found still describe it as subject to definitive documentation/closing conditions.
2 · Reply
TheToaster
TheToaster Sep. 19 at 12:35 PM
$SCLX When have you ever been "right"??? That question is so old Trump wouldnt even r*p* it.
1 · Reply
Latest News on SCLX
Scilex Holding Company Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

Scilex Holding Company Quarterly report: Q2 2026


Scilex Holding Company Quarterly report: Q1 2026

May 20, 2026, 8:00 AM EDT - 4 months ago

Scilex Holding Company Quarterly report: Q1 2026


Scilex Holding Company Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 4 months ago

Scilex Holding Company Proxy statement: Proxy filing


Scilex Holding Company Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Scilex Holding Company Proxy statement: Proxy filing


Scilex Holding Company Annual report: Q4 2025

Apr 10, 2026, 8:00 AM EDT - 5 months ago

Scilex Holding Company Annual report: Q4 2025


Scilex Holding Company Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

Scilex Holding Company Quarterly report: Q3 2025


Scilex Holding Company Proxy statement: Proxy filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

Scilex Holding Company Proxy statement: Proxy filing


Scilex Holding Company Proxy statement: Proxy filing

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Scilex Holding Company Proxy statement: Proxy filing


Scilex Holding Company Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Scilex Holding Company Quarterly report: Q2 2025


Scilex Holding Company Proxy statement: Proxy filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing


Scilex Holding Company Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Scilex Holding Company Quarterly report: Q1 2025


Scilex Holding Company Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Scilex Holding Company Annual report: Q4 2024


Scilex Holding Company Proxy statement: Proxy filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing


Scilex Holding Company Proxy statement: Proxy filing

Feb 26, 2025, 7:00 AM EST - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing


Scilex Holding Company Proxy statement: Proxy filing

Feb 14, 2025, 7:00 AM EST - 1 year ago

Scilex Holding Company Proxy statement: Proxy filing


Sunnybhargava
Sunnybhargava Sep. 21 at 5:00 PM
$CMPS $ENSC $SCLX why after pain week. You pinned the stock and still no data on overdose which completes on Aug 31. And it’s only blood work for pr. It should be here by now. Why manipulation of stock prices to scare Retail. ?
0 · Reply
EnsysceBiosciences
EnsysceBiosciences Sep. 21 at 3:57 PM
$ENSC At PAINWeek, Prof. Richard Langford highlighted the profound and life-altering burden CRPS can have on patients. He shared the journey of a patient who requested amputation of an affected limb, only for symptoms to later migrate to the other lower limb. The patient ultimately became a double amputee and is now an advocate for improved care. “These stories are sadly quite common in the population of those affected.” Cases like this underscore both the complexity of CRPS and the need for new therapeutic approaches as we advance CY200 for CRPS Type 1. $SCLX $CMPS
0 · Reply
Emptybagsofcash
Emptybagsofcash Sep. 21 at 1:49 PM
$SCLX FLAT.
0 · Reply
Loonster
Loonster Sep. 21 at 1:21 PM
$SCLX BITCOIN $85K
0 · Reply
BioCEOsSukk
BioCEOsSukk Sep. 21 at 12:05 AM
$DVLT is anyone talking about the new SEC rule today about tokenization? IMO this is the regulatory win Nate mentioned that'd unlock the $SCLX Biotech Exchange. And if so I think it unlocks a big Scilex PE Consortium buyout, which would exponentially make Datavault worth a lot more because it'd have PE backing - and Scilex JV owns 950k shares they could give to Datavault pre closing that Datavault can monetize to move on the GPU expansion pre Scilex bo closing. All the above might be why Nate is so confident even though the SP is in the toilet...
3 · Reply
Emptybagsofcash
Emptybagsofcash Sep. 20 at 2:58 AM
2 · Reply
TheToaster
TheToaster Sep. 19 at 4:44 PM
$SCLX $SRNE $DVLT Let's not forget "the antibody library..." that ranged from 1 quadrillion up to 10 quadrillion antibodies. Even at the low end its equivalent to storing half a months worth of the ENTIRE global internet traffic. 😆 So many bidders during BK for that gem.
3 · Reply
Tuscion
Tuscion Sep. 19 at 4:31 PM
$DVLT $SCLX 🔥👁️
0 · Reply
Mjust
Mjust Sep. 19 at 2:39 PM
$SCLX $DVLT A similar clarification is needed for DVLT. DVLT has announced very large contracts, partnerships, revenue targets and now a $100M QEST purchase order. But investors should separate PR announcements from completed financial results. Questions I would ask: 1. How much cash has DVLT actually paid into the Available/SanQtum/Qestrel infrastructure, and where did that cash come from? 2. How much of the previously announced ~$750M in tokenization contracts has actually become GAAP-recognized revenue and cash collected? 3. Who is the counterparty behind the $100M QEST PO, what are the performance/payment terms, and how much has actually been paid? 4. How will the economics with Available/AP Cyber affect the amount DVLT actually recognizes or retains? 5. Has SCLX actually funded any of its proposed $120M contribution? The filings I’ve found still describe it as subject to definitive documentation/closing conditions.
2 · Reply
TheToaster
TheToaster Sep. 19 at 12:35 PM
$SCLX When have you ever been "right"??? That question is so old Trump wouldnt even r*p* it.
1 · Reply
Loonster
Loonster Sep. 18 at 6:54 PM
$SCLX Crypto is on a bull breakout
1 · Reply
BioCEOsSukk
BioCEOsSukk Sep. 17 at 9:51 PM
$SCLX over 1.3k out of the 2.9k SCLXW volume today was tiny lots from 1-45 that don't show up as registered volume events nor move the price. Highest total of those I've seen is 738. Something is up IMO...
0 · Reply
BBatteries
BBatteries Sep. 17 at 5:37 PM
$SCLX Correct me if I’m wrong, but SCLX will be paid up to $30 million according to the April agreement after the exact contracted revenue is established
3 · Reply
BBatteries
BBatteries Sep. 17 at 4:13 PM
$SCLX Block a bear, buy a share!! Big reversal has started IMO
2 · Reply
TheToaster
TheToaster Sep. 17 at 11:03 AM
$SCLX RFLMAO at Bull-curious. That is only made funnier by the two clowns responding to peddle stale false hope, which is the product that Ji sells quite successfully for decades now. Sell enough false hope to one individual and you have a company salesman for life. Also, let's not forget the rebate liabilities. There is no hope for this company.
0 · Reply
Slightlysliding
Slightlysliding Sep. 16 at 10:35 PM
$SCLX Challenge for bulls, or even bull-curious, what does this company or constellation of companies Ji has spawned DONE WELL? Companies that DO WELL at products or serviuces are successful, and then of course make investors money. Beyond ALL THE BS on social media can anyone, anywhere, with any sort of thouyght point out what Ji companies actually do well as an investment thesis? No complaining about shorts, or markets, or FDA, or whatever fake conspiracies... As of yet I have not seen one literally in years. SO again, what does this company do well enough to reward investors...???????
2 · Reply
Mjust
Mjust Sep. 16 at 4:42 PM
$SCLX $DVLT $PHOE SEC filings show an interconnected/circular pattern of financing among Ji-linked and related entities among among Scilex, Semnur, Datavault, Vivasor and ACEA/PHOE. Scilex sold 12.5M SMNR shares for $200M in Bitcoin and later used $150M in Bitcoin to purchase DVLT securities. Scilex subsequently pledged DVLT shares as collateral for loans; $9.2M of one loan was paid directly to settle a Datavault obligation, after which Datavault repaid Scilex $9.4M in Bitcoin. Datavault then issued 75.94M DVLT shares to Vivasor in exchange for a private Vivasor equity stake. Datavault initially valued that investment at about $56.2M, then recorded a $55.4M impairment, leaving roughly $0.8M carrying value.
2 · Reply
Mjust
Mjust Sep. 16 at 1:07 PM
$SCLX $DVLT Key facts from the filings: * Scilex extended a $20M credit facility to Vivasor, where Ji is CEO. * On Aug. 20, Scilex transferred 50M DVLT shares at $0.3151/share, creating about $15.76M of debt at 5% interest. * Vivasor had already disposed of about 75.9M DVLT shares by Aug. 19, one day before receiving the new 50M shares. * Separately, Vivasor owes Scilex about $12M for repurchasing Scilex’s Vivasor preferred stock, with about $5M due Sept. 30. * Vivasor reported only about $0.5M cash at June 30, and Datavault recorded a $55.4M impairment on its Vivasor investment. * Ji signed as Vivasor CEO, and the transactions were approved by Scilex’s board/audit committee. The real question is whether Vivasor can repay Scilex.
2 · Reply
BioCEOsSukk
BioCEOsSukk Sep. 16 at 12:28 AM
$SCLX $SRNE C'mon Hank, throw that crusty toaster into the garbage where he belongs!
0 · Reply
dostephe
dostephe Sep. 15 at 9:22 PM
$SCLX CEO Henry loaned private businessmen Henry 50,000,0000 shares of the garbage known as $DVLT at $.31 per share. Has anyone heard from CEO Henry as to whether businessman Henry has the cash to pay back that “loan” now that its value has been cut in half? I love to see a scammer get scammed. Of course he will never pay back SCLX even if DVLT goes to zero but it will be fun to watch him try and wriggle his way out of that debt.
1 · Reply
Emptybagsofcash
Emptybagsofcash Sep. 15 at 8:31 PM
$SCLX I think I've been abandoned by certain top storytellers I dearly looked up to all these years investing in Sorrento dvlt sclx I'm definitely cooked and have lost everything nearly in all three at this point. Hope they all sleep well at night.
3 · Reply
EnsysceBiosciences
EnsysceBiosciences Sep. 15 at 8:17 PM
$ENSC CRPS represents a very different challenge in pain management with no approved therapies. At PAINWeek, the discussion explored the current treatment landscape, the burden this complex condition places on patients and the need for new therapeutic approaches. As Dr. Jeffrey Gudin emphasized: “CRPS has no approved treatments and patients are desperate for a cure rather than symptomatic treatments that most often do not provide relief.” That unmet need is an important part of why CY200 has become a new component of our pipeline as we expand our work beyond opioid safety and into new approaches to chronic pain. $LXRX $SCLX
0 · Reply